Gene-directed therapy in glaucoma may have future clinical applications

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

The framework covers ocular hypertension to severe progression

Laser surgery is an appropriate adjunctive therapy across the continuum of glaucoma care, as well as a safe option for patients who also have cataracts and other complicating factors

Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death

Social determinants of health challenge our existing expectations